Merus Provides 2023 Outlook

Author's Avatar
Jan 08, 2023

- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy